These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38103100)

  • 1. Characteristics and outcomes in elderly patients with non-valvular atrial fibrillation and high bleeding risk: subanalysis of the J-RHYTHM Registry.
    Kodani E; Inoue H; Atarashi H; Okumura K; Yamashita T; Origasa H;
    Heart Vessels; 2024 Apr; 39(4):330-339. PubMed ID: 38103100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of 15-mg Edoxaban on Clinical Outcomes in 3 Age Strata in Older Patients With Atrial Fibrillation: A Prespecified Subanalysis of the ELDERCARE-AF Randomized Clinical Trial.
    Kuroda M; Tamiya E; Nose T; Ogimoto A; Taura J; Imamura Y; Fukuzawa M; Hayashi T; Akao M; Yamashita T; Lip GYH; Okumura K
    JAMA Cardiol; 2022 Jun; 7(6):583-590. PubMed ID: 35416910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of creatinine clearance on outcomes in patients with non-valvular atrial fibrillation: a subanalysis of the J-RHYTHM Registry.
    Kodani E; Atarashi H; Inoue H; Okumura K; Yamashita T; Origasa H;
    Eur Heart J Qual Care Clin Outcomes; 2018 Jan; 4(1):59-68. PubMed ID: 28950373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Laboratory Test Predictors for Major Bleeding in Elderly (≥80 Years) Patients With Nonvalvular Atrial Fibrillation Treated With Edoxaban 15 mg: Sub-Analysis of the ELDERCARE-AF Trial.
    Mikami T; Hirabayashi K; Okawa K; Betsuyaku T; Watanabe S; Imamura Y; Tanizawa K; Hayashi T; Akao M; Yamashita T; Okumura K
    J Am Heart Assoc; 2022 Sep; 11(17):e024970. PubMed ID: 36056729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Low-Dose Edoxaban by Body Weight in Very Elderly Patients With Atrial Fibrillation: A Subanalysis of the Randomized ELDERCARE-AF Trial.
    Akao M; Yamashita T; Fukuzawa M; Hayashi T; Okumura K
    J Am Heart Assoc; 2024 Feb; 13(3):e031506. PubMed ID: 38240204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial.
    Kato ET; Giugliano RP; Ruff CT; Koretsune Y; Yamashita T; Kiss RG; Nordio F; Murphy SA; Kimura T; Jin J; Lanz H; Mercuri M; Braunwald E; Antman EM
    J Am Heart Assoc; 2016 May; 5(5):. PubMed ID: 27207971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparisons of effectiveness and safety between on-label dosing, off-label underdosing, and off-label overdosing in Asian and non-Asian atrial fibrillation patients treated with rivaroxaban: a systematic review and meta-analysis of observational studies.
    Chan YH; Chan CY; Chen SW; Chao TF; Lip GYH
    Europace; 2023 Oct; 25(10):. PubMed ID: 37738425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes and Safety of Very-Low-Dose Edoxaban in Frail Patients With Atrial Fibrillation in the ELDERCARE-AF Randomized Clinical Trial.
    Akashi S; Oguri M; Ikeno E; Manita M; Taura J; Watanabe S; Hayashi T; Akao M; Okumura K; Akishita M; Yamashita T
    JAMA Netw Open; 2022 Aug; 5(8):e2228500. PubMed ID: 35997978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Blood Pressure Visit-to-Visit Variability on Adverse Events in Patients With Nonvalvular Atrial Fibrillation: Subanalysis of the J-RHYTHM Registry.
    Kodani E; Inoue H; Atarashi H; Okumura K; Yamashita T; Otsuka T; Origasa H;
    J Am Heart Assoc; 2021 Jan; 10(1):e018585. PubMed ID: 33372541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial.
    Bohula EA; Giugliano RP; Ruff CT; Kuder JF; Murphy SA; Antman EM; Braunwald E
    Circulation; 2016 Jul; 134(1):24-36. PubMed ID: 27358434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of hemoglobin concentration and platelet count on outcomes of patients with non-valvular atrial fibrillation: A subanalysis of the J-RHYTHM Registry.
    Kodani E; Inoue H; Atarashi H; Okumura K; Yamashita T; Origasa H;
    Int J Cardiol; 2020 Mar; 302():81-87. PubMed ID: 31785960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Blood Pressure Control on Thromboembolism and Major Hemorrhage in Patients With Nonvalvular Atrial Fibrillation: A Subanalysis of the J-RHYTHM Registry.
    Kodani E; Atarashi H; Inoue H; Okumura K; Yamashita T; Otsuka T; Tomita H; Origasa H;
    J Am Heart Assoc; 2016 Sep; 5(9):. PubMed ID: 27620886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Comparison of Inappropriate-Low-Doses Use among 4 Direct Oral Anticoagulants in Patients with Atrial Fibrillation: From the Database of a Single-Center Registry.
    Sato T; Aizawa Y; Fuse K; Fujita S; Ikeda Y; Kitazawa H; Takahashi M; Okabe M
    J Stroke Cerebrovasc Dis; 2018 Nov; 27(11):3280-3288. PubMed ID: 30121155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stroke prevention with direct oral anticoagulants in high-risk elderly atrial fibrillation patients at increased bleeding risk.
    Chao TF; Chan YH; Chiang CE; Tuan TC; Liao JN; Chen TJ; Lip GYH; Chen SA
    Eur Heart J Qual Care Clin Outcomes; 2022 Oct; 8(7):730-738. PubMed ID: 34694379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secondary Prevention of Stroke with Warfarin in Patients with Nonvalvular Atrial Fibrillation: Subanalysis of the J-RHYTHM Registry.
    Kodani E; Atarashi H; Inoue H; Okumura K; Yamashita T; Origasa H;
    J Stroke Cerebrovasc Dis; 2016 Mar; 25(3):585-99. PubMed ID: 26725259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relation of Stroke and Bleeding Risk Profiles to Efficacy and Safety of Edoxaban for Cardioversion of Atrial Fibrillation (from the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation [ENSURE-AF] Study).
    Lip GYH; Merino JL; Dan GA; Themistoclakis S; Ellenbogen KA; De Caterina R; Goudev A; Jin J; Melino M; Winters SM; Goette A
    Am J Cardiol; 2018 Jan; 121(2):193-198. PubMed ID: 29169605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Edoxaban for the management of elderly Japanese patients with atrial fibrillation ineligible for standard oral anticoagulant therapies: Rationale and design of the ELDERCARE-AF study.
    Okumura K; Lip GYH; Akao M; Tanizawa K; Fukuzawa M; Abe K; Akishita M; Yamashita T
    Am Heart J; 2017 Dec; 194():99-106. PubMed ID: 29223441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical phenotypes of older adults with non-valvular atrial fibrillation not treated with oral anticoagulants by hierarchical cluster analysis in the ANAFIE Registry.
    Suzuki S; Yamashita T; Akao M; Atarashi H; Ikeda T; Okumura K; Koretsune Y; Shimizu W; Tsutsui H; Toyoda K; Hirayama A; Yasaka M; Yamaguchi T; Teramukai S; Kimura T; Morishima Y; Takita A; Inoue H
    PLoS One; 2023; 18(2):e0280753. PubMed ID: 36753467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical characteristics and outcomes of dialysis patients with atrial fibrillation: the Fushimi AF Registry.
    Yamashita Y; Takagi D; Hamatani Y; Iguchi M; Masunaga N; Esato M; Chun YH; Itoh H; Nishimura M; Wada H; Hasegawa K; Ogawa H; Abe M; Akao M
    Heart Vessels; 2016 Dec; 31(12):2025-2034. PubMed ID: 26973346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal Dysfunction Affects Anticoagulation Control With Warfarin and Outcomes in Japanese Elderly Patients With Non-Valvular Atrial Fibrillation.
    Inoue H; Kodani E; Atarashi H; Okumura K; Yamashita T; Origasa H;
    Circ J; 2018 Aug; 82(9):2277-2283. PubMed ID: 29984788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.